Brief Title
Tacrolimus and Mycophenolate Mofetil With or Without Sirolimus in Preventing Acute Graft-Versus-Host Disease in Patients Who Are Undergoing Donor Stem Cell Transplant for Hematologic Cancer
Official Title
A Randomized Phase II Study to Determine the Most Promising Postgrafting Immunosuppression for Prevention of Acute GVHD After Unrelated Donor G-CSF Mobilized Peripheral Blood Mononuclear Cell (G-PBMC) Transplantation Using Nonmyeloablative Conditioning for Patients With Hematologic Malignancies A Multi-Center Trial
Brief Summary
This randomized phase II trial studies how well giving tacrolimus and mycophenolate mofetil
(MMF) with or without sirolimus works in preventing acute graft-versus-host disease (GVHD) in
patients undergoing donor stem cell transplant for hematologic cancer. Giving low doses of
chemotherapy, such as fludarabine phosphate, and total-body-irradiation before a donor
peripheral blood stem cell transplant helps stop the growth of cancer cells. It also stops
the patient's immune system from rejecting the donor's stem cells. The donated stem cells may
replace the patient's immune system and help destroy any remaining cancer cells
(graft-versus-tumor effect). Sometimes the transplanted cells from a donor can also make an
immune response against the body's normal cells. Giving MMF and tacrolimus with or without
sirolimus after transplant may stop this from happening.
Detailed Description
PRIMARY OBJECTIVES:
I. To determine which of 3 GVHD prophylaxis regimens results in reduction of acute grades
II-IV GVHD to =< 40%.
SECONDARY OBJECTIVES:
I. Reduce the incidence of non-relapse mortality from infections and GVHD before day 200 to
=< 15%.
II. Reduce the utilization of high-dose corticosteroids compared to protocols 1463, 1641, and
1668.
III. Compare survival and progression-free survival to that achieved under protocols 1463,
1641, and 1668.
OUTLINE:
CONDITIONING: All patients receive fludarabine phosphate intravenously (IV) over 30 minutes
on days -4 to -2 and undergo total-body irradiation on day 0.
TRANSPLANTATION: All patients undergo allogeneic peripheral blood stem cell transplantation
on day 0.
IMMUNOSUPPRESSION: Patients are randomized to 1 of 3 treatment arms.
ARM I: Patients receive tacrolimus IV or orally (PO) every 12 hours on days -3 to 180 with
taper beginning on day 100 in the absence of GVHD. Patients also receive MMF PO every 8 hours
on days 0-29 and then every 12 hours on days 30-96 with taper beginning on day 40 in the
absence of GVHD.
ARM II: Patients receive tacrolimus IV or PO every 12 hours on days -3 to 150 with taper
beginning on day 100 in the absence of GVHD. Patients also receive MMF PO every 8 hours on
days 0-29 and then every 12 hours on days 30-180 with taper beginning on day 150 in the
absence of GVHD.
ARM III: Patients receive tacrolimus and MMF as in arm II. Patients also receive sirolimus PO
once daily on days -3 to 80.
After completion of study treatment, patients are followed up at 6 months and then every year
thereafter.
Study Phase
Phase 2
Study Type
Interventional
Primary Outcome
Number of Participants With Grades II-IV Acute GVHD
Secondary Outcome
Number of Non-Relapse Mortalities
Condition
Myelodysplastic/Myeloproliferative Neoplasm, Unclassifiable
Intervention
Fludarabine Phosphate
Study Arms / Comparison Groups
Arm I (MMF and tacrolimus)
Description: Patients receive tacrolimus IV or PO every 12 hours on days -3 to 180 with taper beginning on day 100 in the absence of GVHD. Patients also receive MMF PO every 8 hours on days 0-29 and then every 12 hours on days 30-96 with taper beginning on day 40 in the absence of GVHD.
Publications
* Includes publications given by the data provider as well as publications identified by National Clinical Trials Identifier (NCT ID) in Medline.
Recruitment Information
Recruitment Status
Drug
Estimated Enrollment
210
Start Date
November 2004
Completion Date
May 8, 2015
Primary Completion Date
May 2011
Eligibility Criteria
Inclusion Criteria:
- Ages > 50 years with hematologic malignancies treatable by unrelated hematopoietic
cell transplant (HCT)
- Ages =< 50 years of age with hematologic diseases treatable by allogeneic HCT who
through pre-existing medical conditions or prior therapy are considered to be at high
risk for regimen related toxicity associated with a conventional transplant (> 40%
risk of transplant related mortality [TRM]) (This criterion can include patients with
a HCT-comorbidity index (CI) score of >= 1; transplants should be approved for these
inclusion criteria by both the participating institutions' patient review committees
such as the Patient Care Conference (PCC) at the Fred Hutchinson Cancer Research
Center (FHCRC) and by the principal investigators at the collaborating centers)
- Patients =< 50 years of age who have received previous high-dose transplantation do
not require patient review committee approvals (All children < 12 years must be
discussed with the FHCRC principal investigator (PI) [Brenda Sandmaier, MD 206
6674961] prior to registration)
- Ages =< 50 years of age with chronic lymphocytic leukemia (CLL); these patients do not
require patient review committee approvals
- Ages =< 50 years of age with hematologic diseases treatable by allogeneic HCT who
refuse a conventional HCT (Transplants must be approved for these inclusion criteria
by both the participating institutions' patient review committee such as PCC at the
FHCRC and by the principal investigators at the collaborating centers)
- The following diseases will be permitted although other diagnoses can be considered if
approved by PCC or the participating institutions' patient review committees and the
principal investigators:
- Aggressive non-Hodgkin lymphomas (NHL) and other histologies such as Diffuse
large B cell NHL not eligible for autologous hematopoietic stem cell transplant
(HSCT), not eligible for conventional myeloablative HSCT, or after failed
autologous HSCT
- Mantle Cell NHL may be treated in first complete response (CR) (Diagnostic lumbar
puncture [LP] required pretransplant)
- Low grade NHL with < 6 month duration of CR between courses of conventional
therapy
- CLL must have either
- Failed to meet National Cancer Institute (NCI) Working Group criteria for
complete or partial response after therapy with a regimen containing
fludarabine phosphate (FLU) (or another nucleoside analog, e.g. Cladribine
[2-CDA], pentostatin) or experience disease relapse within 12 months after
completing therapy with a regimen containing FLU (or another nucleoside
analog);
- Failed FLU-CY-Rituximab (FCR) combination chemotherapy at any time point; or
- Have "17p deletion" cytogenetic abnormality; patients should have received
induction chemotherapy but could be transplanted in 1st CR
- Hodgkin Lymphoma must have received and failed frontline therapy
- Multiple Myeloma must have received prior chemotherapy; consolidation of
chemotherapy by autografting prior to nonmyeloablative HCT is permitted
- Acute Myeloid Leukemia (AML) must have < 5% marrow blasts at the time of
transplant
- Acute Lymphocytic Leukemia (ALL) must have < 5% marrow blasts at the time of
transplant
- Chronic Myeloid Leukemia (CML) patients will be accepted if they are beyond
chronic phase (CP)1 and if they have received previous myelosuppressive
chemotherapy or HCT and have < 5% marrow blasts at time of transplant
- Myelodysplasia (MDS)/Myeloproliferative Syndrome (MPS) patients must have
received previous myelosuppressive chemotherapy or HCT and have < 5% marrow
blasts at time of transplant
- Waldenstrom's Macroglobulinemia must have failed 2 courses of therapy
- DONOR: FHCRC matching allowed will be Grades 1.0 to 2.1: unrelated donors who are
prospectively:
- Matched for human leukocyte antigen (HLA)-A, B, C, DRB1 and DQB1 by high
resolution typing
- Only a single allele disparity will be allowed for HLA-A, B, or C as defined by
high resolution typing
- DONOR: Donors are excluded when preexisting immunoreactivity is identified that would
jeopardize donor hematopoietic cell engraftment; this determination is based on the
standard practice of the individual institution; the recommended procedure for
patients with 10 of 10 HLA allele level (phenotypic) match is to obtain a panel
reactive antibody (PRA) screens to class I and class II antigens for all patients
before HCT; if the PRA shows > 10% activity, then flow cytometric or B and T cell
cytotoxic cross matches should be obtained; the donor should be excluded if any of the
cytotoxic cross match assays are positive; for those patients with an HLA Class I
allele mismatch, flow cytometric or B and T cell cytotoxic cross matches should be
obtained regardless of the PRA results; a positive anti-donor cytotoxic crossmatch is
an absolute donor exclusion
- DONOR: Patient and donor pairs homozygous at a mismatched allele in the graft
rejection vector are considered a two-allele mismatch, i.e., the patient is A*0101 and
the donor is A*0102, and this type of mismatch is not allowed
- DONOR: Only filgrastim (G-CSF) mobilized peripheral blood mononuclear cell (PBMC) only
will be permitted as a HSC source on this protocol
Exclusion Criteria:
- Patients with rapidly progressive intermediate or high grade NHL
- Patients with a diagnosis of chronic myelomonocytic leukemia (CMML)
- Central nervous system (CNS) involvement with disease refractory to intrathecal
chemotherapy
- Presence of circulating leukemic blasts (in the peripheral blood) detected by standard
pathology for patients with AML, MDS, ALL or CML
- Fertile men or women unwilling to use contraceptive techniques during and for 12
months following treatment
- Females who are pregnant or breast-feeding
- Patients with active non-hematological malignancies (except non-melanoma skin cancers)
or those with non-hematological malignancies (except non-melanoma skin cancers) who
have been rendered with no evidence of disease, but have a greater than 20% chance of
having disease recurrence within 5 years
- Fungal infections with radiological progression after receipt of amphotericin B or
active triazole for greater than 1 month
- Cardiac ejection fraction < 35%; ejection fraction is required if age > 50 years or
there is a history of anthracycline exposure or history of cardiac disease
- Diffusion capacity of carbon monoxide (DLCO) < 40%, total lung capacity (TLC) < 40%,
forced expiratory volume in one second (FEV1) < 40% and/or receiving supplementary
continuous oxygen
- The FHCRC PI of the study must approve of enrollment of all patients with pulmonary
nodules
- Patients with clinical or laboratory evidence of liver disease would be evaluated for
the cause of liver disease, its clinical severity in terms of liver function, and the
degree of portal hypertension; patients will be excluded if they are found to have
fulminant liver failure, cirrhosis of the liver with evidence of portal hypertension,
alcoholic hepatitis, esophageal varices, a history of bleeding esophageal varices,
hepatic encephalopathy, uncorrectable hepatic synthetic dysfunction evinced by
prolongation of the prothrombin time, ascites related to portal hypertension, bridging
fibrosis, bacterial or fungal liver abscess, biliary obstruction, chronic viral
hepatitis with total serum bilirubin > 3 mg/dL, or symptomatic biliary disease
- Karnofsky score < 60 or Lansky score < 50
- Patient has poorly controlled hypertension and on multiple antihypertensives
- Human immunodeficiency virus (HIV) positive patients
- Active bacterial or fungal infections unresponsive to medical therapy
- All patients receiving antifungal therapy voriconazole, posaconazole, or fluconazole
and who are then randomized to ARM 3 must have rapamycin reduced according to the
Standard Practice of Antifungal Therapy Guidelines
- The addition of cytotoxic agents for cytoreduction with the exception of tyrosine
kinase inhibitors (such as imatinib), cytokine therapy, hydroxyurea, low dose
cytarabine, chlorambucil, or Rituxan will not be allowed within three weeks of the
initiation of conditioning
- DONOR: Donor (or centers) who will exclusively donate marrow
- DONOR: Donors who are HIV-positive and/or, medical conditions that would result in
increased risk for G-CSF mobilization and harvest of G-PBMC
Gender
All
Ages
N/A - N/A
Accepts Healthy Volunteers
No
Contacts
Brenda Sandmaier, ,
Location Countries
Denmark
Location Countries
Denmark
Administrative Informations
NCT ID
NCT00105001
Organization ID
1938.00
Secondary IDs
NCI-2010-00268
Responsible Party
Principal Investigator
Study Sponsor
Fred Hutchinson Cancer Center
Collaborators
National Cancer Institute (NCI)
Study Sponsor
Brenda Sandmaier, Principal Investigator, Fred Hutchinson Cancer Research Center/University of Washington Cancer Consortium
Verification Date
October 2019